Healthcare Industry News: liposome
News Release - May 8, 2006
Endovasc Announces Agreement with PYRAMID Labs to Manufacture Liprostin for Phase IIIa Trial
HOUSTON--(HSMN NewsFeed)--May 8, 2006--ENDOVASC INC. (OTCBB:EVSC ), today announced that the Company has awarded PYRAMID Laboratories, Inc. a contract to manufacture its lead drug compound, Liprostin, for the upcoming phase IIIa clinical trial for patients suffering from Intermittent Claudication. The GMP documented manufacturing of Liprostin is scheduled to be completed by June 16, 2006.Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1) which is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. Endovasc has submitted its protocol for a phase IIIa clinical trial of Liprostin for the treatment of intermittent claudication, a symptom of Peripheral Arterial Disease, to the FDA. Intermittent claudication causes a cramping sensation in the legs that is present during exercise or walking and occurs as a result of decreased oxygen supply.
"The confirmation of Liprostin's manufacturing marks the achievement of another important step toward commencing our phase IIIa trials this year. The Company, in collaboration with its CRO, has begun the process of contacting investigators at various clinical sites to administer Liprostin. We hope to solidify participating sites for these trials in the coming months," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.
About PYRAMID Laboratories Inc.
PYRAMID Laboratories, Inc. is an independent professional service organization specializing in Contract Aseptic Manufacturing and Analytical Services for the pharmaceutical and biotechnology industries. PYRAMID's manufacturing services include formulation, processing, and aseptic filling capabilities for both vial and syringe as well as lyophilization applications. As an FDA registered Biopharmaceutical facility, PYRAMID is experienced in product development, formulation, manufacturing and supporting laboratory services compliant with GLP and cGMP guidelines. For more information, please visit www.pyramidlabs.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating thru the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor:
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Source: Endovasc, Inc
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.